Literature DB >> 14645149

Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.

Alexander Rosendahl1, Matthaios Speletas, Karin Leandersson, Fredrik Ivars, Paschalis Sideras.   

Abstract

Members of the transforming growth factor (TGF)-beta family play pivotal roles in the control of differentiation, proliferation and tolerance in peripheral T cells. Recently, they have been implicated in thymic selection, but their role is so far not well characterized. In the present study, we demonstrate that specific thymocyte populations are under the influence of either the TGF-beta and/or Activin pathway, and transduce signals into the nucleus via phosphorylated Smad2 (pSmad2). Thymocytes in the medulla and in the subcapsular zone expressed nuclear translocated pSmad2, a hallmark of active TGF-beta/Activin receptor signaling. When analyzed at the cellular level, the pSmad2(+) cells were confined to the double-negative (DN) and single-positive (SP) subpopulations. Moreover, the most immature DN thymocytes (CD44(+)CD25(-) and CD44(+)CD25(+)) expressed higher levels of pSmad2 compared to the more mature DN. In vitro stimulation demonstrated that pure CD44(+)CD25(-), CD44(+)CD25(+) and CD44(+)CD25(+) thymocytes respond to ActivinA, while the mature CD4(+) and CD8(+) SP thymocytes respond to TGF-beta stimulation measured as enhanced phosphorylation of Smad2. Double staining of pSmad2(+) cells with either the Activin type I receptor, ALK4, or the TGF-beta type I receptor, ALK5, demonstrated that pSmad2(+) DN cells exhibited high levels of immunoreactivity to ALK4 and moderate levels of immunoreactivity to the TGF-beta-responsive ALK5 receptor. In sharp contrast, the SP pSmad2(+) cells were predominately ALK5(+). Collectively, our results demonstrate that early and late thymocytes express pSmad2 in the nuclei in vivo. The functional experiments in vitro suggest that members of the TGF-beta family (TGF-beta or Activin) may play important non-redundant roles during different stages of thymopoiesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645149     DOI: 10.1093/intimm/dxg139

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  RhoB deficiency in thymic medullary epithelium leads to early thymic atrophy.

Authors:  Arturo Bravo-Nuevo; Rebekah O'Donnell; Alexander Rosendahl; Jae Hoon Chung; Laura E Benjamin; Chikako Odaka
Journal:  Int Immunol       Date:  2011-08-23       Impact factor: 4.823

Review 2.  Immunoregulation by members of the TGFβ superfamily.

Authors:  WanJun Chen; Peter Ten Dijke
Journal:  Nat Rev Immunol       Date:  2016-11-25       Impact factor: 53.106

3.  Altered expression of Smad proteins in T or NK-cell lymphomas.

Authors:  Jai Hyang Go
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

4.  Activins and inhibins: novel regulators of thymocyte development.

Authors:  Paula Licona-Limón; German Alemán-Muench; Jesus Chimal-Monroy; Marina Macías-Silva; Eduardo A García-Zepeda; Martin M Matzuk; Teresa I Fortoul; Gloria Soldevila
Journal:  Biochem Biophys Res Commun       Date:  2009-02-13       Impact factor: 3.575

5.  Inhibins tune the thymocyte selection process by regulating thymic stromal cell differentiation.

Authors:  Ebzadrel Carbajal-Franco; Marisol de la Fuente-Granada; Germán R Alemán-Muench; Eduardo A García-Zepeda; Gloria Soldevila
Journal:  J Immunol Res       Date:  2015-04-20       Impact factor: 4.818

6.  Betaglycan (TβRIII) is expressed in the thymus and regulates T cell development by protecting thymocytes from apoptosis.

Authors:  German R Aleman-Muench; Valentin Mendoza; Kaye Stenvers; Eduardo A Garcia-Zepeda; Fernando Lopez-Casillas; Chander Raman; Gloria Soldevila
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

Review 7.  A Tale from TGF-β Superfamily for Thymus Ontogeny and Function.

Authors:  Arnon Dias Jurberg; Larissa Vasconcelos-Fontes; Vinícius Cotta-de-Almeida
Journal:  Front Immunol       Date:  2015-09-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.